Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference

September 25, 2019

 LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 25, 2019-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 2019 Cantor Global Healthcare Conference. The presentation is scheduled to begin at 11:15 a.m. ET on Friday, October 4, 2019.

A live webcast of the presentation can be accessed on the “Investors & Media” section of the Aldeyra website, www.aldeyra.com. An audio replay will be available following the live presentation and will be archived on the website for 90 days.

 About Aldeyra Therapeutics 
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Source: Aldeyra Therapeutics, Inc.

 Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcmullin@aldeyra.com
 
Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com